Cordis Corp.
Data supports performance of CYPHER Sirolimus-eluting Coronary Stent
Published in Drug Law Weekly, April 6th, 2004
Four-year findings from the first-in-man pilot study and 3-year findings from RAVEL, the clinical trial in Europe and Latin America, were presented at the American College of Cardiology 53rd annual scientific session.
Both studies were funded by Cordis Corp., a Johnson & Johnson company.
"The results of these two studies continue to demonstrate the long-term safety and efficacy of the CYPHER Stent," said Dennis Donohoe, MD, worldwide vice president of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2004-04-06)
More Articles from Drug Law Weekly
- AdvancePCS
Drug benefits clients beat national drug cost trend - Alnylam Pharmaceuticals, Inc.
Isis Pharmaceuticals enters RNAi alliance - Antidepressants
Consumer group seeking ban on antidepressant sues U.S. government - Ciphergen Biosystems, Inc.
ProteinChip system receives medical device certification in China - Cutting Edge Information
Early generic drug defense planning could save $80B in market share - Drug Testing
Medical ethicists critique study of drug testing in schools - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
